Anti-Human IL-17A (Secukinumab) - Fc Muted™ (I1215-500ug)

IL-17 is a group of proinflammatory cytokines (IL-17A to IL-17F) released by T helper 17 (Th17) cells1. IL-17A is the key effector cytokine of the group1 and is involved in normal inflammatory and immune responses2. Additionally, increased IL-17A plays an important role in the pathogenesis of ankylosing spondylitis (AS), a chronic autoimmune inflammatory disease that primarily affects the axial skeleton2, and in the progression of psoriatic arthritis1. Secukinumab is a fully humanized monoclonal antibody that binds selectively to IL-17A and inhibits its interaction with the IL-17 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines2. Secukinumab was developed as an IL-17A inhibitor for the treatment of AS and has been approved for the treatment of AS, plaque psoriasis, and psoriatic arthritis. In AS, the levels of a variety of biomarkers (CRP, S100A8, and S100A9) decrease with secukinumab treatment along with symptoms. Secukinumab was generated in transgenic mice engineered to express the human IgG/κ repertoire in lieu of the murine immunoglobulin repertoire using recombinant human IL-17 as immunogen3. Murine hybridoma cells were obtained that secrete the human IgG/κ antibody and selection for activity against IL-17A was performed. Secukinumab may have significant cross-reactivity with IL-17F, depending on the chosen experimental conditions5.